KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$919000.0.

  • Castle Biosciences' Cash from Financing Activities fell 20966.59% to -$919000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.8 million, marking a year-over-year decrease of 19427.49%. This contributed to the annual value of $6.1 million for FY2024, which is 36714.53% up from last year.
  • Castle Biosciences' Cash from Financing Activities amounted to -$919000.0 in Q3 2025, which was down 20966.59% from $101000.0 recorded in Q2 2025.
  • Castle Biosciences' 5-year Cash from Financing Activities high stood at $10.6 million for Q1 2024, and its period low was -$5.4 million during Q4 2024.
  • Moreover, its 5-year median value for Cash from Financing Activities was $226000.0 (2023), whereas its average is $442421.1.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 69523.81% in 2022, then surged by 176222.22% in 2024.
  • Castle Biosciences' Cash from Financing Activities (Quarter) stood at $126000.0 in 2021, then plummeted by 695.24% to -$750000.0 in 2022, then tumbled by 339.6% to -$3.3 million in 2023, then plummeted by 63.33% to -$5.4 million in 2024, then surged by 82.93% to -$919000.0 in 2025.
  • Its Cash from Financing Activities was -$919000.0 in Q3 2025, compared to $101000.0 in Q2 2025 and -$1.6 million in Q1 2025.